C027P: Pembrolizumab Biosimilar, PD-1 Monoclonal Antibody
Recombinant Humanized IgG4 Monoclonal Antibody.
Specificity/Sensitivity: The research grade pembrolizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1 or PD1), antagonizing its interaction with its known ligands PD-L1 or PDL1, and PD-L2 or PDL2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by pembrolizumab.